EUVIMEDEUVIMED entdecken
Open Access

Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy

Kimberly J Nelson iD, Terrence L Smalley iD, Terri Messier iD, Rajesh Gumpena, Uma Gandhi, Stephanie Milczarek iD, Aida Habibovic, Hattie Hoffman, Victoria Gibson, Robert J Hondal iD, W Todd Lowther iD, Brian Cunniff iD

Science Advances · 31.10.2025 · 11 (44)

DOI: 10.1126/sciadv.ady4492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 31.10.2025. Verfasst von Kimberly J Nelson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Center for Structural Biology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, …. Hauptthemen laut MEDLINE: Peroxiredoxin III, Antineoplastic Agents, Enzyme Inhibitors, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Covalent inhibitors that are approved and marketed drugs exploit a wide array of warheads and reactions with amino acid side chain–based nucleophiles. Thiostrepton (TS) inhibits the peroxidase activity of the mitochondrial antioxidant protein peroxiredoxin 3 by forming a covalent crosslink between the two active site cysteine residues. Peroxiredoxin 3 inactivation increases reactive oxygen species levels, induces cancer cell death in preclinical models, and shows promise in an ongoing clinical trial for malignant mesothelioma using direct pleural infusion. We report the identification of the minimal fragment of TS that contains tandem dehydro-alanine (DHA) moieties and maintains anticancer activity while losing interactions with three alternative targets of intact TS. Biochemical, kinetic, cellular, and structural studies demonstrate that this fragment is a mechanism-based peroxiredoxin inhibitor. These findings represent a promising start toward a pro-oxidant approach for cancer therapy. Moreover, the data support that the DHA moiety should be added to the covalent warhead arsenal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peroxiredoxin IIIAntineoplastic AgentsEnzyme InhibitorsNeoplasmsHumansCell Line, TumorReactive Oxygen SpeciesModels, Molecular

Substanzen

Peroxiredoxin IIIAntineoplastic AgentsEnzyme InhibitorsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Biochemistry, Center for Structural Biology, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Medical Center Blvd., Winston-Salem, NC 27157, USA.
  • Center for Redox Biology and Medicine, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
  • Department of Pathology and Laboratory Medicine, University of Vermont Cancer Center, Larner College of Medicine, Burlington, VT 05405, USA.
  • Wake Forest University, Biochemistry and Molecular Biology Program, Winston-Salem, NC 27109, USA.
  • Department of Biochemistry, University of Vermont, Burlington, VT, 05405, USA.

ORCID-Profile: Kimberly J Nelson, Terrence L Smalley, Terri Messier, Stephanie Milczarek, Robert J Hondal, W Todd Lowther, Brian Cunniff

Zitieren

APA

Nelson, K. J., Smalley, T. L., Messier, T., Gumpena, R., Gandhi, U., Milczarek, S., Habibovic, A., Hoffman, H., Gibson, V., Hondal, R. J., Lowther, W. T., & Cunniff, B. (2025). Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy. Science Advances, 11(44). https://doi.org/10.1126/sciadv.ady4492

Vancouver

Nelson KJ, Smalley TL, Messier T, Gumpena R, Gandhi U, Milczarek S, et al. Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy. Science Advances. 2025;11(44). doi:10.1126/sciadv.ady4492

BibTeX
@article{Nelson2025,
  author = {Nelson, Kimberly J and Smalley, Terrence L and Messier, Terri and Gumpena, Rajesh and Gandhi, Uma and Milczarek, Stephanie and Habibovic, Aida and Hoffman, Hattie and Gibson, Victoria and Hondal, Robert J and Lowther, W Todd and Cunniff, Brian},
  title = {Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {44},
  doi = {10.1126/sciadv.ady4492}
}
Kostenlos starten →